Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.

ABSTRACT:

Background

Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in children younger than 12 years of age.

Methods

A phase 1, dose-finding study and an ongoing phase 2-3 randomized trial are being conducted to investigate the safety, immunogenicity, and efficacy of two doses of the BNT162b2 vaccine administered 21 days apart in children 6 months to 11 years of age. We present results for 5-to-11-year-old children. In the phase 2-3 trial, participants were randomly assigned in a 2:1 ratio to receive two doses of either the BNT162b2 vaccine at the dose level identified during the open-label phase 1 study or placebo. Immune responses 1 month after the second dose of BNT162b2 were immunologically bridged to those in 16-to-25-year-olds from the

SUBMITTER: Walter EB 

PROVIDER: S-EPMC8609605 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature